Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients
This study is currently recruiting participants.
Verified February 2013 by Sanofi
Sponsor:
Sanofi
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT01690403
First received: September 13, 2012
Last updated: February 20, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Primary Objective:
- To evaluate the effect of single and repeated administration of rifapentine given as daily or weekly regimen on steady-state pharmacokinetic parameters of efavirenz, emtricitabine and tenofovir given as a fixed dose combination (ATRIPLA™ ).
Secondary Objective:
- To evaluate the safety and tolerability of concomitant administration of rifapentine and ATRIPLA™ given to HIV+ patients
| Condition | Intervention | Phase |
|---|---|---|
|
Tuberculosis |
Drug: rifapentine (M000473) Drug: EFZ EMT TDF |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | An Open-label, Non-randomized, Single Sequence, Two Periods, Four-treatment, Three Parallel Groups Pharmacokinetic Interaction Study of Repeated Oral Doses (Daily or Weekly Regimen) of Rifapentine on ATRIPLA™ (Fixed Dose Combination of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate) Given to HIV+ Patients |
Resource links provided by NLM:
Drug Information available for:
Rifapentine
Emtricitabine
Tenofovir
Efavirenz
Tenofovir Disoproxil Fumarate
Atripla
U.S. FDA Resources
Further study details as provided by Sanofi:
Primary Outcome Measures:
- To determine PK parameters Cmax, Cmin and AUC0-24 for efavirenz (EFZ), emtricitabine (EMT) and tenofovir (TDF) [ Time Frame: Day-2, Day 1 and Day 21 for cohorts 1 and 3, and on Day -2 ,Day 1 and Day 16 for cohort 2 ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- To determine PK parameters t1/2z, tmax for efavirenz (EFZ), emtricitabine (EMT) and tenofovir (TDF) [ Time Frame: Day-2, Day 1 and Day 21 for cohorts 1 and 3, and on Day -2, Day 1 and Day 16 for cohort 2 ] [ Designated as safety issue: No ]
- To determine PK parameters tlag, CL/F for efavirenz (EFZ), emtricitabine (EMT) and tenofovir (TDF) [ Time Frame: Day-2, Day 1 and Day 21 for cohorts 1 and 3, and on Day -2, Day 1 and Day 16 for cohort 2 ] [ Designated as safety issue: No ]
- To determine PK parameter for AUC0-10 for efavirenz (EFZ), emtricitabine (EMT) and tenofovir (TDF) [ Time Frame: Day -2 and Day 1 for cohorts 1 and 3 ] [ Designated as safety issue: No ]
- To determine PK parameters Ctrough for rifapentine and 25-desacetyl- rifapentine (25-DR) [ Time Frame: Cohort 2: Day 1, 8, and 15 ] [ Designated as safety issue: No ]
- To determine PK parameters C8h for rifapentine and 25-desacetyl- rifapentine (25-DR) [ Time Frame: Cohort 2: Day 1, 8, and 15 ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 36 |
| Study Start Date: | September 2012 |
| Estimated Study Completion Date: | April 2013 |
| Estimated Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: cohort 1
Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 1).
|
Drug: rifapentine (M000473)
Pharmaceutical form:tablet Route of administration: oral Pharmaceutical form:tablet Route of administration: oral Other Name: ATRIPLA™
|
|
Experimental: cohort 2
Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 2).
|
Drug: rifapentine (M000473)
Pharmaceutical form:tablet Route of administration: oral Pharmaceutical form:tablet Route of administration: oral Other Name: ATRIPLA™
|
|
Experimental: cohort 3 (optional)
Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 3).
|
Drug: rifapentine (M000473)
Pharmaceutical form:tablet Route of administration: oral Pharmaceutical form:tablet Route of administration: oral Other Name: ATRIPLA™
|
Detailed Description:
- Screening to admission: up to 21 days
Admission to the end of the follow-up: up to 41 days
- Period 1: Treatment period of 15 days with ATRIPLA™ (background therapy). Patients should receive the same regimen and dose of ATRIPLA™ during the all study screening and period 1.
- Period 2: Treatment over a period of 21 days in co-administration with rifapentine.
- Follow up: 3 to 5 days after the last rifapentine administration.
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria :
- HIV+ male and female patients receiving ATRIPLA™ aged 18 to 55 years old with a CD4 count cells of at least 350
Exclusion criteria:
- Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, haematological (patients with porphyria), neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynaecologic (if female), or infectious disease, or signs of acute illness other than HIV disease.
- Active or latent tuberculosis infection
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01690403
Contacts
| Contact: For site information, send an email with site number to | Contact-Us@sanofi-aventis.com |
Locations
| United States, New York | |
| Investigational Site Number 840001 | Recruiting |
| Buffalo, New York, United States, 14202 | |
Sponsors and Collaborators
Sanofi
Investigators
| Study Director: | Clinical Sciences & Operations | Sanofi |
More Information
No publications provided
| Responsible Party: | Sanofi |
| ClinicalTrials.gov Identifier: | NCT01690403 History of Changes |
| Other Study ID Numbers: | INT12291, U1111-1131-1992 |
| Study First Received: | September 13, 2012 |
| Last Updated: | February 20, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Tuberculosis Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections Rifapentine Rifampin Tenofovir disoproxil Tenofovir Efavirenz, emtricitabine, tenofovir disoproxil fumarate drug combination Antibiotics, Antitubercular Anti-Bacterial Agents |
Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Antitubercular Agents Leprostatic Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Nucleic Acid Synthesis Inhibitors Reverse Transcriptase Inhibitors Anti-Retroviral Agents Antiviral Agents Anti-HIV Agents |
ClinicalTrials.gov processed this record on March 03, 2013
